New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
1. to investigate, whether one of the two alternative therapy strategies (antibiotic plus
immunostimulation versus antibiotic plus immunosuppression) in chronic reactive
arthritis is therapeutical superior to conventionel standardtherapy (DMARD).
2. to investigate, whether one or more of the different therapy strategies cause an altered
detection of bacterial DNA in the joint or colon.
3. to measure the antigen-specific and -unspecific immune response (predominantly t-cell
response) during therapy and correlate it with the clinical course.
4. to gain knowledge from these analyses and the clinical course concerning the
pathogenesis and the point of attack for possible therapies in chronic reactive
arthritis.
5. to compare cytokine-profiles of CD4- and CD8-positive T-cells from patients treated with
infliximab to those treated with etanercept.